Clopidogrel and PPIs

The joint manufacturers of Plavix (clopidogrel) have sent a letter to healthcare professionals regarding the interaction between clopidogrel and proton pump inhibitors (PPIs).

They state that the concomitant use of these drugs should be avoided unless absolutely necessary as clopidogrel may be less effective in patients receiving clopidogrel and a PPI.

Clopidogrel is a pro-drug that is metabolised by cytochrome P450 2C19 to its active form. PPIs may inhibit this isoenzyme and therefore interfere with the antiplatelet activity of clopidogrel.

The manufacturers are conducting further studies to characterise the potential effects of PPIs and CYP2C19 genetic factors on the activity of the drug. In the meantime, patients should continue to take clopidogrel as directed.

Advice to healthcare professionals from the MHRA remains the same. All patients currently receiving clopidogrel and PPIs should be reviewed at their next appointment; concomitant use of these medicines should be avoided. PPIs should only be prescribed within their licensed indications where possible and prescribers should check that patients prescribed clopidogrel are not taking over-the-counter omeprazole.

View Plavix drug record

Further information: Sanofi-aventis

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more